Explore 3 Stock Ideas & Industry Insights Download Free Report

8082-737-676
Shopping Cart 0
countryflagUK
Login

Scynexis Inc

Healthcare US SCYX

4.67USD
-0.43(8.43%)

Last update at 2026-06-03T20:00:00Z

Day Range

4.635.09
LowHigh

52 Week Range

1.353.87
LowHigh

Fundamentals

  • Previous Close 5.10
  • Market Cap88.78M
  • Volume66684
  • P/E Ratio1.11
  • Dividend Yield-%
  • EBITDA74.42M
  • Revenue TTM140.38M
  • Revenue Per Share TTM2.93
  • Gross Profit TTM 12.85M
  • Diluted EPS TTM2.11

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Analyst Recommendations

Financials

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Income before tax -67.50900M -35.95400M -58.33300M -53.71000M -19.20400M
Minority interest - - - - -
Net income -62.80900M -32.86600M -55.18500M -55.23400M -12.46800M
Selling general administrative 62.96M 49.92M 14.63M 10.65M 8.68M
Selling and marketing expenses - - - - -
Gross profit 4.46M 12.85M - 0.12M 0.26M
Reconciled depreciation 0.61M 0.38M 0.11M 0.11M 0.05M
Ebit -85.75700M -60.82500M -51.14900M -48.92100M -29.01600M
Ebitda -85.32200M -61.72500M -52.31800M -48.63800M -28.96300M
Depreciation and amortization 0.43M -0.90000M -1.16900M 0.28M 0.05M
Non operating income net other - 27.54M -6.00300M -3.80300M 12.40M
Operating income -85.75700M -60.82500M -51.14900M -48.92100M -29.98300M
Other operating expenses 90.85M 73.99M 50.81M 49.04M 30.24M
Interest expense 5.20M 2.66M 1.18M 0.99M 2.05M
Tax provision -4.70000M -3.08800M -3.14800M 0.00000M -6.73600M
Interest income 1.42M 0.02M 0.19M 0.81M 0.97M
Net interest income -5.37200M -3.93900M -2.19300M -1.35200M -1.08700M
Extraordinary items - - - - -
Non recurring - - - - -
Other items - - - - -
Income tax expense -4.70000M -3.08800M -3.14800M 1.52M -6.73600M
Total revenue 5.09M 13.16M 0.00000M 0.12M 0.26M
Total operating expenses 90.22M 73.68M 50.81M 49.04M 30.24M
Cost of revenue 0.63M 0.31M - - 0.00000M
Total other income expense net 18.25M 24.87M -7.18400M -4.78900M 11.87M
Discontinued operations - - - - -
Net income from continuing ops -62.80900M -32.86600M -55.18500M -53.71000M -12.46800M
Net income applicable to common shares - -32.86600M -55.18500M -53.71000M -12.46800M
Preferred stock and other adjustments - - - - -
Breakdown 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Type yearly yearly yearly yearly yearly
Date 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Total assets 128.41M 87.81M 119.84M 102.54M 57.15M
Intangible assets - 0.41M 1.06M - -
Earning assets - - - - -
Other current assets 5.55M 0.06M 0.00400M 0.37M 0.67M
Total liab 55.45M 84.58M 78.58M 79.78M 44.26M
Total stockholder equity 72.96M 3.23M 41.26M 22.76M 12.89M
Deferred long term liab - - 0.15M 0.19M 0.07M
Other current liab 7.62M 11.40M 5.70M 17.56M 3.80M
Common stock 0.04M 0.04M 0.03M 0.02M 0.10M
Capital stock 0.04M 0.04M 0.03M 0.02M 0.10M
Retained earnings -355.24700M -422.28800M -359.47900M -326.61300M -271.42800M
Other liab - - 21.41M 33.59M 21.60M
Good will - - - - -
Other assets - - 7.66M 4.03M 1.16M
Cash 34.43M 45.81M 104.48M 93.04M 41.92M
Cash and equivalents - - - - -
Total current liabilities 16.30M 17.62M 13.62M 26.40M 11.01M
Current deferred revenue 1.19M - - 4.14M -
Net debt -19.35000M 2.78M -60.85800M -73.19900M -27.03600M
Short term debt 0.34M 0.28M 0.07M 0.05M 0.04M
Short long term debt - - - - -
Short long term debt total 15.08M 48.60M 43.63M 19.84M 14.88M
Other stockholder equity 428.17M 425.49M 400.70M 349.35M 284.23M
Property plant equipment - - 0.11M 3.30M 0.41M
Total current assets 102.12M 79.06M 109.38M 98.21M 52.40M
Long term investments 23.59M - - - -
Net tangible assets - - 40.20M 22.76M 12.89M
Short term investments 40.31M 27.69M - 0.00000M 6.49M
Net receivables 21.83M 2.10M 0.86M 2.88M -
Long term debt 12.16M 45.39M 28.75M 16.52M 11.52M
Inventory 0.00000M 0.90M 0.46M 1.92M -
Accounts payable 7.15M 5.94M 7.85M 4.64M 7.18M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income 0.00000M - - - -0.17200M
Additional paid in capital - - - - -
Common stock total equity - - 0.03M 0.02M 0.10M
Preferred stock total equity - - - - -
Retained earnings total equity - - -359.47900M -326.61300M -271.42800M
Treasury stock - - - - -
Accumulated amortization - - - - -
Non currrent assets other 0.17M 5.75M 6.49M 1.03M 1.16M
Deferred long term asset charges - - 0.15M 0.19M 0.07M
Non current assets total 26.30M 8.75M 10.46M 4.33M 4.75M
Capital lease obligations 2.92M 3.20M 3.27M 3.33M 3.36M
Long term debt total - - 28.75M - 11.52M
Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Investments -27.38900M -1.17200M 6.47M 26.24M -0.23800M
Change to liabilities - 7.70M -2.29600M 5.09M -0.03400M
Total cashflows from investing activities - -1.17200M 6.47M 26.24M -0.80300M
Net borrowings - 28.75M 10.00M -1.22600M -2.27200M
Total cash from financing activities 48.60M 67.12M 94.00M 42.30M 29.42M
Change to operating activities - 6.54M -0.92200M 3.25M -6.36700M
Net income -62.80900M -32.86600M -55.18500M -53.71000M -12.46800M
Change in cash -58.67000M 11.39M 51.12M 30.43M 0.30M
Begin period cash flow 104.70M 93.31M 42.19M 11.77M 11.47M
End period cash flow 46.03M 104.70M 93.31M 42.19M 11.77M
Total cash from operating activities -79.88300M -54.56000M -49.35400M -38.11900M -28.32300M
Issuance of capital stock 47.25M 38.56M 90.55M 46.34M 31.66M
Depreciation 0.61M 0.38M 0.11M 0.11M 0.05M
Other cashflows from investing activities - -1.17200M - 26.24M -0.23800M
Dividends paid - - -10.02800M - -
Change to inventory -0.43600M -5.29200M -5.29200M -5.29200M -5.29200M
Change to account receivables -1.24000M -0.86100M -0.86100M -0.86100M -0.86100M
Sale purchase of stock - 38.57M -0.20800M 46.39M 31.70M
Other cashflows from financing activities 1.38M 29.82M 14.18M 13.19M -2.23300M
Change to netincome - -26.72200M 7.74M 5.80M -10.05000M
Capital expenditures 0.00900M 1.17M 0.00400M 0.00400M 0.56M
Change receivables - -0.86100M - - -
Cash flows other operating - 1.79M -0.12800M 3.43M -6.14100M
Exchange rate changes - - - - -
Cash and cash equivalents changes - 11.39M 51.12M 30.43M 0.30M
Change in working capital 0.76M 3.15M -3.21800M 8.35M -6.40100M
Stock based compensation 3.69M 2.09M 2.22M 1.83M 1.82M
Other non cash items -22.13000M 1.50M 2.00M 1.34M 0.42M
Free cash flow -79.89200M -55.73200M -49.35800M -38.11900M -28.88800M

Peer Comparison

Sector: Healthcare Industry: Drug Manufacturers - Specialty & Generic

Company Change (USD) Price (USD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to Revenue (x) Enterprise Value to EBITDA (x)
SCYX
Scynexis Inc		 -0.43 8.43% 4.67 1.11 2.25 0.39 0.75 0.0076 -0.0667
ZTS
Zoetis Inc		 1.20 1.57% 77.59 40.18 30.96 10.67 17.60 11.27 26.18
MKKGY
Merck KGaA ADR		 0.58 1.91% 31.01 21.25 14.93 3.10 2.14 3.60 12.98
MKGAF
MERCK Kommanditgesellschaft auf Aktien		 - -% 153.91 21.73 14.95 3.16 2.15 3.56 12.82
GALDY
GALDERMA GROUP AG		 -0.79 1.89% 40.92 74.21 41.67 8.64 5.55 9.15 42.22

Reports Covered

Stock Research & News

View All

Profile

SCYNEXIS, Inc., a biotechnology company, develops medicines to overcome and prevent difficult-to-treat and drug-resistant infections in the United States. It offers BREXAFEMME for the treatment of patients with vulvovaginal candidiasis (VVC) and recurrent VVC. The company's lead product candidate is Ibrexafungerp, an intravenous drug for the treatment of invasive candidiasis and/or candidemia, refractory invasive fungal infections, invasive aspergillosis, VVC, and recurrent VVC. It also develops SCY-247 to treat systemic fungal diseases. The company has licensing and collaboration agreements with GlaxoSmithKline Intellectual Property (No. 3) Limited, Merck Sharp & Dohme Corp., Hansoh (Shanghai) Health Technology Co., Ltd., Jiangsu Hansoh Pharmaceutical Group Company Limited, and R-Pharm, CJSC for the development, manufacture, and commercialization of ibrexafungerp. SCYNEXIS, Inc. was formerly known as SCYNEXIS Chemistry & Automation, Inc. and changed its name to SCYNEXIS, Inc. in June 2002. The company was incorporated in 1999 and is headquartered in Jersey City, New Jersey.

Scynexis Inc

1 Evertrust Plaza, Jersey City, NJ, United States, 07302-6548

Key Executives

Name Title Year Born
Dr. Marco Taglietti M.D. CEO, Pres & Director 1960
Mr. David Gonzalez Angulo M.D. Chief Medical Officer 1965
Mr. Ivor Macleod CPA, M.B.A. Chief Financial Officer 1962
Mr. Scott Sukenick J.D. Gen. Counsel & Corp. Sec. 1978
Debbie Etchison Exec. Director of Communications NA
Mr. David Gonzalez Angulo M.D. CEO, President & Director 1965
Mr. Scott Sukenick J.D. Chief Legal Officer & Corporate Secretary 1978
Mr. Ivor Macleod CPA, M.B.A. Chief Financial Officer 1961
Debbie Etchison Executive Director of Communications NA
Ms. Daniella Gigante Vice President of Human Resources & Information Technology NA

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

We use cookies to help us improve, promote, and protect our services. By continuing to use this site, we assume you consent to our Cookies Policy. For more information, read our Privacy Policy and Terms and Conditions